Skip to main content

Quidel Prices Senior Notes Offering

NEW YORK (GenomeWeb) — Quidel today announced the pricing of its previously announced underwritten public offering of $150 million in convertible senior notes due 2020.

The notes will pay interest at a rate of 3.25 percent per year, payable semiannually on June 15 and Dec. 15 of each year, beginning on June 15, 2015. The notes will mature on Dec. 15, 2020, unless earlier repurchased by Quidel or converted.

The conversion rate will initially be approximately 31.2 shares of common stock for each $1,000 principal amount of notes, representing an initial conversion price of about $32.06 per share, Quidel said.

Quidel also expects to grant underwriters a 30-day option to purchase up to an additional $22.5 million aggregate principal amount of the notes, solely to cover over-allotments, if any.

The San Diego-based in vitro diagnostics firm said it plans to use the net proceeds from the offering for working capital and other general corporate purposes, which may include acquisitions of products, technologies, or businesses, and opportunistic repurchases of shares of its common stock.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.